Blog
By Kevin E. Noonan -- The Federal Circuit affirmed the Patent Trial and Appeal Board's (PTAB) claim construction (and inter partes review (IPR) decision invalidating claims for obviousness) in it recent Genentech, Inc. v.
In withdrawing the 2013 statement, the new 2019 guidance by the DOJ, NIST and the USPTO states the obvious, i.e. that there is no difference in the law between F/RAND assured standard essential patents and all other patents.
Inter Partes Review (IPR) proceedings before the Patent Trial and Appeal Board (PTAB) often occur in parallel to district court cases.
By Donald Zuhn -- On March 11, World Health Organization Director-General Tedros Adhanom declared that the COVID-19 outbreak "can be characterized as a pandemic," cautioning that the WHO has "rung the alarm bell loud and clear." At the time of the
By Kevin E. Noonan -- The Federal Circuit continued its recent willingness to affirm findings of infringement under the doctrine of equivalents (see, e.g., "Eli Lilly & Co. v. Hospira, Inc. (Fed. Cir. 2019)"), in Galderma Laboratories, L.P.
March 31, 2020 - "Preserving Businesses During the COVID-19 Recession: Understanding the Business and Tax Impact of the CARES Act" (myLawCLE) - 1:00 to 3:00 pm (ET) April 2, 2020 - "Indefiniteness after Samsung v.
Since China announced the first fatality caused by a virus about which little was known at the time, coronavirus and the disease it causes, COVID-19, has grown to pandemic proportions.
MyLawCLE will be offering a live video broadcast entitled "Preserving Businesses During the COVID-19 Recession: Understanding the Business and Tax Impact of the CARES Act" on March 31, 2020 from 1:00 to 3:00 pm (ET). Eric L. Green, Jeffrey M.
Earlier this week, the Supreme Court handed down its ruling in Allen v. Cooper, which relates to photos and videos of the sunken remains of the Queen Anne’s Revenge, the centuries-old ship once captained by the famed pirate Blackbeard.
LexisNexis® and IPWatchdog will be offering a webinar on "Antiviral Patents -- How prepared are we to combat novel viral diseases?" on April 2, 2020 at 12:00 pm (ET).